NBIX - Neurocrine Q1 revenue beats Street gets FDA okay for Ingrezza Sprinkle
2024-05-01 12:47:00 ET
More on Neurocrine Biosciences
- Neurocrine Biosciences, Inc. (NBIX) Q1 2024 Earnings Call Transcript
- Neurocrine: Success Continues To Roll In With Positive MDD Treatment Data
- Neurocrine Biosciences Heads Into A Catalyst-Rich 2024 With Additional Upside
- Neurocrine Biosciences Q1 2024 Earnings Preview
- Neurocrine launches CAH community website ahead of FDA filing